{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:07:20Z","timestamp":1790017640438,"version":"4.0.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073255"],"award-info":[{"award-number":["82073255"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.phrs.2025.108081","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T23:35:27Z","timestamp":1767224127000},"page":"108081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Mitochondrial pyruvate dehydrogenase kinase 1 drives bevacizumab resistance and malignant phenotype of TNBC by enhancing mitophagy"],"prefix":"10.1016","volume":"224","author":[{"given":"Yan","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuli","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3985-2908","authenticated-orcid":false,"given":"Kejia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4250-674X","authenticated-orcid":false,"given":"Tingmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.phrs.2025.108081_bib1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2018","journal-title":"Int J. Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2025.108081_bib2","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.phrs.2025.108081_bib3","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2025.108081_bib4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","article-title":"Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Gradishar","year":"2020","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"15","key":"10.1016\/j.phrs.2025.108081_bib5","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clinical Cancer Research Official Journal American Association Cancer Research"},{"issue":"7","key":"10.1016\/j.phrs.2025.108081_bib6","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest"},{"issue":"12","key":"10.1016\/j.phrs.2025.108081_bib7","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"20","key":"10.1016\/j.phrs.2025.108081_bib8","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.phrs.2025.108081_bib9","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2025.108081_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.clbc.2011.03.005","article-title":"Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial","volume":"11","author":"Robert","year":"2011","journal-title":"Clin. Breast Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2025.108081_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2010.30.2794","article-title":"Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials","volume":"29","author":"Miles","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"10.1016\/j.phrs.2025.108081_bib12","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.19.00555","article-title":"Phase III randomized trial of chemotherapy with or without bevacizumab in patients with recurrent or metastatic head and neck cancer","volume":"37","author":"Argiris","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.phrs.2025.108081_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157399","article-title":"Targeting FAP\u03b1-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis models","volume":"132","author":"Qi","year":"2022","journal-title":"J. Clin. Invest"},{"issue":"6","key":"10.1016\/j.phrs.2025.108081_bib14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2025.108081_bib15","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3892\/or_00001027","article-title":"Cycling hypoxia increases U87 glioma cell radioresistance via ROS induced higher and long-term HIF-1 signal transduction activity","volume":"24","author":"Hsieh","year":"2010","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2025.108081_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/nrm3028","article-title":"Mechanisms of mitophagy","volume":"12","author":"Youle","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.phrs.2025.108081_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.12.009","article-title":"MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells","volume":"40","author":"Limagne","year":"2022","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.phrs.2025.108081_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41422-022-00766-z","article-title":"Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria","volume":"33","author":"Xie","year":"2023","journal-title":"Cell Res."},{"issue":"5","key":"10.1016\/j.phrs.2025.108081_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cells8050493","article-title":"Mitophagy in cancer: a tale of adaptation","volume":"8","author":"Vara-Perez","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2025.108081_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40170-015-0130-8","article-title":"Mitophagy and cancer","volume":"3","author":"Chourasia","year":"2015","journal-title":"Cancer Metab."},{"issue":"3","key":"10.1016\/j.phrs.2025.108081_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","article-title":"Metabolic reprogramming: a cancer hallmark even warburg did not anticipate","volume":"21","author":"Ward","year":"2012","journal-title":"Cancer Cell"},{"issue":"48","key":"10.1016\/j.phrs.2025.108081_bib22","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.1074\/jbc.270.48.28989","article-title":"Diversity of the pyruvate dehydrogenase kinase gene family in humans","volume":"270","author":"Gudi","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2025.108081_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2017.07.014","article-title":"Paraoxonase 2 facilitates pancreatic cancer growth and metastasis by stimulating GLUT1-mediated glucose transport","volume":"67","author":"Nagarajan","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2025.108081_bib24","article-title":"CircRAD54L2 promotes triple-negative breast cancer progression by regulating the miR-888 family\/PDK1 axis","volume":"312","author":"He","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2025.108081_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121077","article-title":"Novel shikonin derivatives suppress cell proliferation, migration and induce apoptosis in human triple-negative breast cancer cells via regulating PDK1\/PDHC axis","volume":"310","author":"Chen","year":"2022","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.phrs.2025.108081_bib26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/bjc.2012.527","article-title":"PDK1 inhibition is a novel therapeutic target in multiple myeloma","volume":"108","author":"Fujiwara","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2025.108081_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117722","article-title":"Nucleus-located PDK1 regulates growth, invasion and migration of breast cancer cells","volume":"253","author":"Gan","year":"2020","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.phrs.2025.108081_bib28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.cmet.2015.08.007","article-title":"PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer","volume":"22","author":"Dupuy","year":"2015","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.phrs.2025.108081_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","article-title":"HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia","volume":"3","author":"Kim","year":"2006","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.phrs.2025.108081_bib30","first-page":"1119","article-title":"CoCl2 increases the expression of hypoxic markers HIF-1\u03b1, VEGF and CXCR4 in breast cancer MCF-7 cells","volume":"15","author":"Li","year":"2017","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.phrs.2025.108081_bib31","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1038\/s41467-021-22971-x","article-title":"An RFC4\/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.phrs.2025.108081_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2017.09.022","article-title":"Mitophagy controls the activities of tumor suppressor p53 to regulate hepatic cancer stem cells","volume":"68","author":"Liu","year":"2017","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.phrs.2025.108081_bib33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41392-021-00790-2","article-title":"Fis1 phosphorylation by Met promotes mitochondrial fission and hepatocellular carcinoma metastasis","volume":"6","author":"Yu","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"26","key":"10.1016\/j.phrs.2025.108081_bib34","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.phrs.2025.108081_bib35","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1167\/iovs.07-1175","article-title":"Interaction between bevacizumab and murine VEGF-A: a reassessment","volume":"49","author":"Yu","year":"2008","journal-title":"Invest Ophthalmol. Vis. Sci."},{"issue":"12","key":"10.1016\/j.phrs.2025.108081_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278951","article-title":"Assessment of mouse VEGF neutralization by ranibizumab and aflibercept","volume":"17","author":"Ichiyama","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.phrs.2025.108081_bib37","article-title":"PDK1 promotes breast cancer progression by enhancing the stability and transcriptional activity of HIF-1\u03b1","volume":"11","author":"Wei","year":"2023","journal-title":"Genes Dis."},{"issue":"7","key":"10.1016\/j.phrs.2025.108081_bib38","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/mc.23542","article-title":"PDK1-stabilized LncRNA SPRY4-IT1 promotes breast cancer progression via activating NF-\u03baB signaling pathway","volume":"62","author":"Zhang","year":"2023","journal-title":"Mol. Carcinog."},{"issue":"1-2","key":"10.1016\/j.phrs.2025.108081_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2016.11.042","article-title":"Prohibitin 2 is an inner mitochondrial membrane mitophagy receptor","volume":"168","author":"Wei","year":"2016","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.phrs.2025.108081_bib40","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/15548627.2019.1628520","article-title":"PHB2 (prohibitin 2) promotes PINK1-PRKN\/Parkin-dependent mitophagy by the PARL-PGAM5-PINK1 axis","volume":"16","author":"Yan","year":"2019","journal-title":"Autophagy"},{"issue":"10","key":"10.1016\/j.phrs.2025.108081_bib41","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.7150\/thno.55672","article-title":"Cellular senescence in hepatocellular carcinoma induced by a long non-coding RNA-encoded peptide PINT87aa by blocking FOXM1-mediated PHB2","volume":"11","author":"Xiang","year":"2021","journal-title":"Theranostics"},{"issue":"Pt 2","key":"10.1016\/j.phrs.2025.108081_bib42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1042\/BST0330367","article-title":"PDH kinase inhibitors: a novel therapy for Type II diabetes?","volume":"33","author":"Mayers","year":"2005","journal-title":"Biochem Soc. Trans."},{"issue":"3","key":"10.1016\/j.phrs.2025.108081_bib43","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4093\/dmj.2015.39.3.188","article-title":"Pyruvate dehydrogenase kinases: therapeutic targets for diabetes and cancers","volume":"39","author":"Jeoung","year":"2015","journal-title":"Diabetes Metab. J."},{"issue":"11","key":"10.1016\/j.phrs.2025.108081_bib44","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood-2010-02-269134","article-title":"PKCzeta decreases eNOS protein stability via inhibitory phosphorylation of ERK5","volume":"116","author":"Nigro","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.phrs.2025.108081_bib45","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/cr.2016.159","article-title":"Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2","volume":"27","author":"Liang","year":"2016","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.phrs.2025.108081_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.devcel.2020.10.025","article-title":"Global and site-specific effect of phosphorylation on protein turnover","volume":"56","author":"Wu","year":"2020","journal-title":"Dev. Cell"},{"issue":"8","key":"10.1016\/j.phrs.2025.108081_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.str.2007.07.001","article-title":"Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol","volume":"15","author":"Kato","year":"2007","journal-title":"Structure"},{"issue":"5","key":"10.1016\/j.phrs.2025.108081_bib48","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.phrs.2025.108081_bib49","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108081_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2014.12.007","article-title":"PINK1 and Parkin control localized translation of respiratory chain component mRNAs on mitochondria outer membrane","volume":"21","author":"Gehrke","year":"2015","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.phrs.2025.108081_bib51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/jnci\/djz211","article-title":"A systematic review and meta-analysis of bevacizumab in first-line metastatic breast cancer: lessons for research and regulatory enterprises","volume":"112","author":"Hey","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.phrs.2025.108081_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25042060","article-title":"Therapeutic targeting of hypoxia-inducible factors in cancer","volume":"25","author":"Musleh Ud Din","year":"2024","journal-title":"Int J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.phrs.2025.108081_bib53","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1158\/1078-0432.CCR-17-0874","article-title":"Bevacizumab induces acute hypoxia and cancer progression in patients with refractory breast cancer: multimodal functional imaging and multiplex cytokine analysis","volume":"23","author":"Ueda","year":"2017","journal-title":"Clinical Cancer Research Official Journal American Association Cancer Research"},{"issue":"15","key":"10.1016\/j.phrs.2025.108081_bib54","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1158\/0008-5472.CAN-15-3435","article-title":"Preclinical efficacy of bevacizumab with CRLX101, an investigational nanoparticle-drug conjugate, in treatment of metastatic triple-negative breast cancer","volume":"76","author":"Pham","year":"2016","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.phrs.2025.108081_bib55","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1038\/sj.bjc.6604356","article-title":"PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer","volume":"98","author":"Wigfield","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2025.108081_bib56","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccell.2016.07.004","article-title":"Mitochondrial Akt regulation of hypoxic tumor reprogramming","volume":"30","author":"Chae","year":"2016","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.phrs.2025.108081_bib57","doi-asserted-by":"crossref","first-page":"962","DOI":"10.7150\/jca.34330","article-title":"Pyruvate dehydrogenase kinase 1 interferes with glucose metabolism reprogramming and mitochondrial quality control to aggravate stress damage in cancer","volume":"11","author":"Deng","year":"2020","journal-title":"J. Cancer"},{"issue":"17","key":"10.1016\/j.phrs.2025.108081_bib58","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1158\/1078-0432.CCR-07-5023","article-title":"The double-edged sword of autophagy modulation in cancer","volume":"15","author":"White","year":"2009","journal-title":"Clinical Cancer Research Official Journal American Association Cancer Research"},{"issue":"1","key":"10.1016\/j.phrs.2025.108081_bib59","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41392-023-01503-7","article-title":"The mitophagy pathway and its implications in human diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2025.108081_bib60","article-title":"Mitochondrial dynamics, mitophagy, and mitochondria-endoplasmic reticulum contact sites crosstalk under hypoxia","volume":"10","author":"Wang","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"7","key":"10.1016\/j.phrs.2025.108081_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/cells11071193","article-title":"Induction of mitochondrial fragmentation and mitophagy after neonatal hypoxia-ischemia","volume":"11","author":"Nair","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.phrs.2025.108081_bib62","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-018-0575-7","article-title":"Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma","volume":"11","author":"Zheng","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"15","key":"10.1016\/j.phrs.2025.108081_bib63","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1182\/blood-2016-04-708750","article-title":"Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML","volume":"128","author":"Dany","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.phrs.2025.108081_bib64","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1083\/jcb.200809125","article-title":"Parkin is recruited selectively to impaired mitochondria and promotes their autophagy","volume":"183","author":"Narendra","year":"2008","journal-title":"J. Cell Biol."},{"issue":"10","key":"10.1016\/j.phrs.2025.108081_bib65","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.tcb.2016.05.008","article-title":"Deciphering the molecular signals of PINK1\/parkin mitophagy","volume":"26","author":"Nguyen","year":"2016","journal-title":"Trends Cell Biol."},{"issue":"8","key":"10.1016\/j.phrs.2025.108081_bib66","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.4161\/auto.6.8.13426","article-title":"p62\/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both","volume":"6","author":"Narendra","year":"2010","journal-title":"Autophagy"},{"issue":"7565","key":"10.1016\/j.phrs.2025.108081_bib67","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature14893","article-title":"The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy","volume":"524","author":"Lazarou","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2025.108081_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188568","article-title":"Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy","volume":"1876","author":"Anwar","year":"2021","journal-title":"Biochim. Et. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.phrs.2025.108081_bib69","article-title":"PGAM5-mediated PHB2 dephosphorylation contributes to diabetic cardiomyopathy by disrupting mitochondrial quality surveillance","volume":"2022","author":"Zou","year":"2022","journal-title":"Res. (Wash. D. C. )"},{"issue":"6","key":"10.1016\/j.phrs.2025.108081_bib70","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000806","article-title":"Mitochondrial Aurora kinase A induces mitophagy by interacting with MAP1LC3 and Prohibitin 2","volume":"4","author":"Bertolin","year":"2021","journal-title":"Life Sci. Alliance"},{"issue":"21","key":"10.1016\/j.phrs.2025.108081_bib71","first-page":"4843","article-title":"Restricted mitochondrial protein acetylation initiates mitochondrial autophagy","volume":"126","author":"Webster","year":"2013","journal-title":"J. Cell Sci."},{"issue":"6","key":"10.1016\/j.phrs.2025.108081_bib72","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1080\/15548627.2021.1975914","article-title":"The multifaceted regulation of mitophagy by endogenous metabolites","volume":"18","author":"Zhang","year":"2021","journal-title":"Autophagy"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825005067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825005067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:24:45Z","timestamp":1773959085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825005067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":72,"alternative-id":["S1043661825005067"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108081","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitochondrial pyruvate dehydrogenase kinase 1 drives bevacizumab resistance and malignant phenotype of TNBC by enhancing mitophagy","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108081"}}